SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average – Time to Sell?

SCYNEXIS, Inc. (NASDAQ:SCYX) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.38 and traded as low as $1.15. SCYNEXIS shares last traded at $1.17, with a volume of 112,058 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised SCYNEXIS from a “sell” rating to a “hold” rating in a report on Friday, November 8th.

SCYNEXIS Price Performance

The business’s 50 day moving average price is $1.14 and its 200-day moving average price is $1.38. The company has a market cap of $44.40 million, a P/E ratio of -1.58 and a beta of 1.52.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in SCYNEXIS in the 3rd quarter worth approximately $25,000. JPMorgan Chase & Co. acquired a new position in shares of SCYNEXIS in the 4th quarter valued at $49,000. Geode Capital Management LLC grew its holdings in shares of SCYNEXIS by 10.0% in the 3rd quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock valued at $594,000 after buying an additional 36,405 shares during the period. Finally, AMH Equity Ltd grew its holdings in shares of SCYNEXIS by 4.3% in the 4th quarter. AMH Equity Ltd now owns 626,052 shares of the company’s stock valued at $758,000 after buying an additional 26,052 shares during the period. Institutional investors own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.